Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GPR3 | P46089 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.43 |
| ▸ | TOP2A | P11388 | 2/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 2/20 | 0.39 |
| ▸ | CCND1 | P24385 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10500769 | 0.77 | TOP2A (0.55) | KDM4EGPR3PDPK1TOP2ACDK4 | |
| SCHEMBL30214465 | 0.77 | TOP2A (0.55) | KDM4EGPR3PDPK1TOP2ACDK4 | |
| SCHEMBL159417 | 0.77 | KDM4E (0.63) | KDM4EGPR3PDPK1TOP2AALDH1A1 | |
| SCHEMBL14127595 | 0.76 | MEN1 (0.49) | KDM4EGPR3PDPK1TOP2APDGFRB | |
| SCHEMBL29599662 | 0.76 | MEN1 (0.49) | KDM4EGPR3PDPK1TOP2APDGFRB | |
| Ammonia Solution, Strong SCHEMBL28354795 | 0.75 | KDM4E (0.61) | KDM4EGPR3PDPK1TOP2AALDH1A1 | |
| SCHEMBL38663443 | 0.75 | AHR (0.45) | KDM4ECDK4CCND1ALDH1A1TDP1 | |
| SCHEMBL2870080 | 0.75 | KDM4E (0.50) | KDM4EGPR3PDPK1TOP2APDGFRB | |
| SCHEMBL28986555 | 0.75 | AHR (0.45) | KDM4ECDK4CCND1ALDH1A1TDP1 | |
| SCHEMBL13659576 | 0.75 | PARP1 (0.50) | KDM4EGPR3PDPK1TOP2ACDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2336315-B1 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION AS (DK) | 2017-07-19 | — | — | EP | claimed |
| EP-2336315-A2 | Enzymatic encoding methods for efficient synthesis of large libraries | Nuevolution A/S (DK) | 2011-06-22 | — | — | EP | claimed |
| JP-10212289-A | — | — | None | — | — | JP | disclosed |
| US-11702652-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2023-07-18 | — | — | US | disclosed |
| CN-111548276-B | Preparation method of 2,6-dibromoaniline | 宁夏大学 | 2022-12-16 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-115010717-A | Complete synthesis preparation method of lycorine (+/-) -alpha-lycorane | 宁夏大学 | 2022-09-06 | — | — | CN | disclosed |
| CN-113350292-B | Preparation for improving water dispersibility of lycorine, prolonging half-life period of lycorine and improving antitumor activity of lycorine and application thereof | 天津中医药大学 | 2022-07-26 | — | — | CN | disclosed |
| CN-108478571-B | Application of lycorine in preparing broad-spectrum anti-coronavirus medicine | 中国疾病预防控制中心病毒病预防控制所 | 2022-04-01 | — | — | CN | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| CN-113350292-A | Preparation for improving water dispersibility of lycorine, prolonging half-life period of lycorine and improving antitumor activity of lycorine and application thereof | 天津中医药大学 | 2021-09-07 | — | — | CN | disclosed |
| CN-1319967-C | 2-acylaminothiazole derivative or salt thereof | YAMANOUCHI PHARMA CO LTD (JP) | 2007-06-06 | — | — | CN | disclosed |
| WO-2007054783-A2 | COMPOSITIONS AND METHODS FOR TREATING THROMBOCYTOPENIA | ASTELLAS PHARMA INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| CN-1835948-A | 2-acylaminothiazole derivative or its salt | YAMANOUCHI PHARMA CO LTD (JP) | 2006-09-20 | — | — | CN | disclosed |
| US-20050153977-A1 | 2-Acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2005-07-14 | — | — | US | disclosed |
| CN-1639157-A | 2-acylaminothiazole derivative or salt thereof | YAMANOUCHI PHARMA CO LTD (JP) | 2005-07-13 | — | — | CN | disclosed |
| EP-1466912-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-10-13 | — | — | EP | disclosed |
| US-20040077697-A1 | 2-Acylaminothiazole derivative or its salt | ASTELLAS PHARMA INC. (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1357116-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR ITS SALT | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-10-29 | — | — | EP | disclosed |
| JP-H10212289-A | PYRROLOPHENANTHRIDINE DERIVATIVE | KYOWA HAKKO KOGYO CO LTD | 1998-08-11 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153977-A1 | 2-Acylaminothiazole derivative or salt thereof | MPL, JAK2, ABL1 | KDM4E 1499/4885GPR3 1339/4885PDPK1 2023/4885 |
| US-20040077697-A1 | 2-Acylaminothiazole derivative or its salt | THPO, MPL, JAK2 | KDM4E 1570/4885GPR3 4049/4885PDPK1 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.